DBV Technologies H1 net loss widens to $98 million
DBVT•H1 loss widens as expenses rise
DBV Technologies posted a net loss of USD 98 million for the six months ended June 30, 2026, widening from USD 69 million a year earlier.
Operating income slipped to USD 1.6 million from USD 2.2 million, on lower French research tax credit income as the focus shifts to commercial readiness.
R&D expense rose to USD 64.6 million from USD 55.2 million, while operating expenses climbed to USD 100.1 million from USD 69.9 million.
Cash position and funding outlook
Cash and cash equivalents totaled USD 174.9 million at June 30, 2026, with funding expected into the third quarter of 2027.
VIASKIN Peanut Patch regulatory timeline
FDA talks continued for the VIASKIN Peanut Patch BLA in children 4-7, with submission now expected in the third quarter of 2026.
Related News
Elutia Signs Definitive Agreement To Sell Simpliderm in Transaction Valued At Up To $11 Million, Strengthening Balance Sheet Ahead Of NXT-41X Launch
ELUT•
First Carolina Financial Services Chief Rev. & Strategy Officer Douglas Andrew Mathieson files initial beneficial ownership statement
FCBM•
